达雷妥尤单抗一线与二线治疗不适合移植老年多发性骨髓瘤的成本效果
基于MAIA试验,采用Markov模型从美国支付方角度比较不适合移植初诊多发性骨髓瘤患者一线使用达雷妥尤单抗(DRd)与保留至二线使用的成本效果。一线达雷妥尤单抗较二线策略增加0.52 QALY和0.66贴现生命年,增量成本322,836美元,ICER为618,018美元/QALY。在150,000美元/QALY支付阈值下,达雷妥尤单抗价格需下降67%才具成本效果。
要点
- 一线达雷妥尤单抗较二线策略增加0.52 QALY,增量成本322,836美元。
- ICER为618,018美元/QALY,高于150,000美元/QALY的支付阈值。
- 达雷妥尤单抗降价67%方可在150,000美元/QALY阈值下具成本效果。
核心结论
- 当前价格下,不适合移植患者一线使用达雷妥尤单抗可能不具成本效果。
- 延迟达雷妥尤单抗至后续线治疗可在不显著损害临床结局下限制医疗费用。
- 需成熟总生存数据更全面评估该场景的成本效果。
研究设计与样本
- 研究采用Markov模型,从美国支付方角度比较一线与二线使用达雷妥尤单抗的成本和临床结局。
- 目标人群为不适合移植的多发性骨髓瘤患者。
- 转移概率通过参数生存模型从随机试验中估计。
主要发现
- 一线达雷妥尤单抗较二线策略增加0.52 QALY和0.66贴现生命年。
- 两种策略的终身直接医疗费用分别为1,434,937美元和1,112,101美元。
- 一线达雷妥尤单抗的增量成本为322,836美元,ICER为618,018美元/QALY。
关键数值与推荐
- 在 willingness-to-pay 阈值150,000美元/QALY下,达雷妥尤单抗价格需降低67%才能使一线策略具成本效果。
临床怎么用
- 在资源有限环境中,可考虑将达雷妥尤单抗保留至二线使用以控制成本。
- 决策时应结合当地药品价格和支付阈值评估一线使用达雷妥尤单抗的成本效果。
局限性
- 研究基于模型假设和试验数据外推,需成熟总生存数据验证。
- 分析采用美国支付方视角,结果可能不适用于其他医疗体系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd). However, daratumumab is a costly treatment and is administered indefinitely until disease progression. Therefore, it is unclear whether it is cost-effective to use daratumumab in the first-line setting compared with reserving its use until later lines of therapy. METHODS: We created a Markov model to compare healthcare costs and clinical outcomes of transplant-ineligible patients treated with daratumumab in the first-line setting compared with a strategy of reserving daratumumab until the second-line. We estimated transition probabilities from randomized trials using parametric survival modeling. Lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for first-line daratumumab versus second-line daratumumab from a US payer perspective. RESULTS: First-line daratumumab was associated with an improvement of 0.52 QALYs and 0.66 discounted life-years compared with second-line daratumumab. While both treatment strategies were associated with considerable lifetime expenditures ($1,434,937 v $1,112,101 in US dollars), an incremental cost of $322,836 for first-line daratumumab led to an ICER of $618,018 per QALY. The cost of daratumumab would need to be decreased by 67% for first-line daratumumab to be cost-effective at a willingness-to-pay threshold of $150,000 per QALY. CONCLUSION: Using daratumumab in the first-line setting for transplant-ineligible patients may not be cost-effective under current pricing. Delaying daratumumab until subsequent lines of therapy may be a reasonable strategy to limit healthcare costs without significantly compromising clinical outcomes. Mature overall survival data are necessary to more fully evaluate cost-effectiveness in this setting.
引用
- Patel KK, Giri S, Parker TL, et al. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. J Clin Oncol. 2021. PMID: 33411586. doi:10.1200/JCO.20.01849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。